论文部分内容阅读
目的目前有关肿瘤坏死因子受体相关因子6(tumor necrosis receptor-associated factor 6,TRAF6)在胃癌相关领域的研究仍有限。本研究通过检测胃癌患者组织中TRAF6表达,探讨其与患者营养状况和预后的关系,为胃癌治疗提供新思路。方法采用逆转录-聚合酶链反应、蛋白质印迹法、酶联免疫吸附试验检测2008-01-01-2013-06-30浙江省人民医院102例胃癌患者及53例腹腔良性疾病患者组织(腹直肌、血清)中TRAF6mRNA和蛋白的表达情况,并结合临床资料分析其对胃癌患者营养状况及预后的影响。结果胃癌患者腹直肌中TRAF6 mRNA的相对表达量(3.89±0.09)较腹腔良性疾病患者(1.77±1.08)明显升高,t=13.050,P<0.001。蛋白质印迹法结果显示,胃癌患者腹直肌中TRAF6蛋白表达较腹腔良性疾病患者明显升高,P<0.05。胃癌患者血清中TRAF6蛋白的相对表达量(4.89±1.09)较腹腔良性疾病患者(2.78±1.18)明显升高,t=14.595,P<0.001。胃癌患者血清中TRAF6蛋白表达水平与患者体质量丢失(χ~2=12.901,P<0.001)、血清白蛋白(χ~2=17.422,P<0.001)及血红蛋白水平(χ~2=4.886,P=0.027)有关。胃癌患者血清中TRAF6蛋白表达水平与患者胃癌病理类型(χ~2=6.154,P=0.046)、淋巴结转移(χ~2=10.237,P=0.001)及TNM分期(χ~2=7.727,P=0.005)有关。胃癌患者血清中TRAF6蛋白表达水平与患者生存率有关,χ~2=6.641,P=0.010。结论胃癌患者腹直肌及血清中TRAF6mRNA和蛋白表达升高,且血清中TRAF6蛋白表达水平患者的营养状况及预后存在关联。TRAF6可能与胃癌患者癌性恶病质的发生发展有关。
Objective The current research on tumor necrosis receptor-associated factor 6 (TRAF6) is still limited in gastric cancer related fields. This study detected the expression of TRAF6 in gastric cancer patients, and explored its relationship with the nutritional status and prognosis of patients, and provided new ideas for the treatment of gastric cancer. Methods Reverse transcription-polymerase chain reaction, Western blot and enzyme-linked immunosorbent assay were used to detect the tissues of 102 patients with gastric cancer and 53 patients with benign abdominal diseases from January 2005 to January 2013 in Zhejiang Provincial People’s Hospital. The expression of TRAF6 mRNA and protein in muscle and serum was combined with clinical data to analyze its effect on the nutritional status and prognosis of gastric cancer patients. Results The relative expression of TRAF6 mRNA in the rectus abdominus of gastric cancer patients (3.89±0.09) was significantly higher than that in benign patients (1.77±1.08), t=13.050, P<0.001. Western blotting results showed that the expression of TRAF6 protein in rectus abdominis of gastric cancer patients was significantly higher than that in patients with benign abdominal disease (P<0.05). The relative expression of TRAF6 protein in serum of patients with gastric cancer (4.89±1.09) was significantly higher than that of patients with benign abdominal disease (2.78±1.18), t=14.595, P<0.001. The serum level of TRAF6 protein in patients with gastric cancer was associated with loss of body mass (χ~2=12.901, P<0.001), serum albumin (χ~2=17.422, P<0.001), and hemoglobin level (χ~2=4.886,P = 0.027) relevant. The expression of TRAF6 protein in serum of patients with gastric cancer and pathological types of gastric cancer (χ~2=6.154, P=0.046), lymph node metastasis (χ~2=10.237, P=0.001) and TNM staging (χ~2=7.727, P= 0.005) related. The expression of TRAF6 protein in serum of gastric cancer patients was related to the survival rate of patients, χ~2=6.641, P=0.010. Conclusion The expression of TRAF6 mRNA and protein in the rectus abdominus and serum of gastric cancer patients is increased. The serum nutritional level and the prognosis of TRAF6 protein are correlated. TRAF6 may be related to the occurrence and development of cancer cachexia in gastric cancer patients.